CA3210320A1 - Synthesis of a bruton's tyrosine kinase inhibitor - Google Patents

Synthesis of a bruton's tyrosine kinase inhibitor

Info

Publication number
CA3210320A1
CA3210320A1 CA3210320A CA3210320A CA3210320A1 CA 3210320 A1 CA3210320 A1 CA 3210320A1 CA 3210320 A CA3210320 A CA 3210320A CA 3210320 A CA3210320 A CA 3210320A CA 3210320 A1 CA3210320 A1 CA 3210320A1
Authority
CA
Canada
Prior art keywords
compound
formula
ibrutinib
amino
pyrazolo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3210320A
Other languages
English (en)
French (fr)
Inventor
Cyril BENHAIM
Wei Chen
Erick Goldman
Andras Horvath
Philip Pye
Mark S. Smyth
Erik J. Verner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Pharmacyclics LLC
Original Assignee
Janssen Pharmaceutica NV
Pharmacyclics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV, Pharmacyclics LLC filed Critical Janssen Pharmaceutica NV
Publication of CA3210320A1 publication Critical patent/CA3210320A1/en
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA3210320A 2015-01-14 2016-01-14 Synthesis of a bruton's tyrosine kinase inhibitor Pending CA3210320A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562103507P 2015-01-14 2015-01-14
US62/103,507 2015-01-14
CA2971460A CA2971460C (en) 2015-01-14 2016-01-14 Synthesis of a bruton's tyrosine kinase inhibitor

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA2971460A Division CA2971460C (en) 2015-01-14 2016-01-14 Synthesis of a bruton's tyrosine kinase inhibitor

Publications (1)

Publication Number Publication Date
CA3210320A1 true CA3210320A1 (en) 2016-07-21

Family

ID=56406389

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2971460A Active CA2971460C (en) 2015-01-14 2016-01-14 Synthesis of a bruton's tyrosine kinase inhibitor
CA3210320A Pending CA3210320A1 (en) 2015-01-14 2016-01-14 Synthesis of a bruton's tyrosine kinase inhibitor

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CA2971460A Active CA2971460C (en) 2015-01-14 2016-01-14 Synthesis of a bruton's tyrosine kinase inhibitor

Country Status (16)

Country Link
US (6) US20180009814A1 (enExample)
EP (1) EP3245208A4 (enExample)
JP (2) JP2018502077A (enExample)
KR (1) KR20170102887A (enExample)
CN (2) CN113816962A (enExample)
AU (2) AU2016206693A1 (enExample)
BR (1) BR112017015206B1 (enExample)
CA (2) CA2971460C (enExample)
HK (1) HK1246293A1 (enExample)
IL (4) IL322449A (enExample)
MA (1) MA41350A (enExample)
MX (2) MX394327B (enExample)
RU (1) RU2017128308A (enExample)
SG (2) SG10201906517VA (enExample)
WO (1) WO2016115356A1 (enExample)
ZA (1) ZA201704338B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107207519B (zh) * 2015-02-12 2019-11-08 正大天晴药业集团股份有限公司 伊布替尼的制备方法
EP3424505A4 (en) 2016-03-04 2019-10-16 Taiho Pharmaceutical Co., Ltd. PREPARATION AND COMPOSITION FOR THE TREATMENT OF MALIGNANT TUMORS
US11883404B2 (en) 2016-03-04 2024-01-30 Taiho Pharmaceuticals Co., Ltd. Preparation and composition for treatment of malignant tumors
CN109206426B (zh) * 2017-07-06 2021-10-08 上海复星星泰医药科技有限公司 吡唑并嘧啶类化合物的制备方法
EP3661939B1 (en) 2017-08-01 2021-07-21 Boehringer Ingelheim International GmbH Intermediate compounds and methods
CN107814804A (zh) * 2017-10-27 2018-03-20 广州科锐特生物科技有限公司 依鲁替尼的制备方法
TWI790364B (zh) 2018-03-19 2023-01-21 日商大鵬藥品工業股份有限公司 包含烷基硫酸鈉之醫藥組合物
MX2020011527A (es) 2018-05-03 2021-02-26 Juno Therapeutics Inc Terapia de combinación de una terapia de células t-receptor de antígeno quimérico (car) y un inhibidor de cinasa.
JP6944496B2 (ja) 2018-10-22 2021-10-06 ファイザー・インク ピロロ[2,3−d]ピリミジントシル酸塩、その結晶形態、ならびにその製造方法および中間体
WO2020095452A1 (ja) 2018-11-09 2020-05-14 大鵬薬品工業株式会社 ジメトキシベンゼン化合物の製造方法
CN109988175A (zh) * 2019-04-28 2019-07-09 梯尔希(南京)药物研发有限公司 一种依鲁替尼-d5的制备方法
MX2021014245A (es) 2019-05-21 2022-01-06 Janssen Pharmaceutica Nv Procedimientos y productos intermedios para preparar un inhibidor de btk.
JP7658916B2 (ja) * 2019-05-21 2025-04-08 ヤンセン ファーマシューティカ エヌ.ベー. Btk阻害剤を調製するためのプロセス及び中間体
US20240092785A1 (en) 2021-01-21 2024-03-21 Synthon B.V. Process for making ibrutinib
CN114853662B (zh) * 2021-02-05 2024-01-12 四川青木制药有限公司 手性肼基哌啶衍生物的制备方法
US20250302954A1 (en) 2022-05-11 2025-10-02 Celgene Corporation Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
WO2023242384A1 (en) 2022-06-17 2023-12-21 Krka, D.D., Novo Mesto Crystalline form of ibrutinib

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4550214A (en) * 1981-01-05 1985-10-29 Polaroid Corporation Blocked vinyl biphenyl compounds
US4874822A (en) * 1988-04-07 1989-10-17 Minnesota Mining And Manufacturing Company Process for the acrylamidoacylation of alcohols
KR101164258B1 (ko) * 2003-12-23 2012-07-11 아스텍스 테라퓨틱스 리미티드 단백질 키나아제 조절제로서의 피라졸 유도체
NZ601278A (en) * 2006-09-22 2013-09-27 Pharmacyclics Inc Inhibitors of Bruton's tyrosine kinase
CN103319488A (zh) * 2007-03-28 2013-09-25 环状药物公司 布鲁顿氏酪氨酸激酶抑制剂
US7741330B1 (en) * 2009-10-12 2010-06-22 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase
EA201590296A1 (ru) * 2012-07-30 2015-07-30 Консерт Фармасьютикалс Инк. Дейтерированный ибрутиниб
CN103121999A (zh) * 2012-08-29 2013-05-29 苏州迪飞医药科技有限公司 一种酪氨酸激酶抑制剂pci-32765的合成方法
US9156847B2 (en) * 2013-03-15 2015-10-13 Janssen Pharmaceutica Nv Processes and intermediates for preparing a medicament
US8957080B2 (en) * 2013-04-09 2015-02-17 Principia Biopharma Inc. Tyrosine kinase inhibitors
CN103626774B (zh) * 2013-11-20 2015-11-04 苏州明锐医药科技有限公司 伊鲁替尼的制备方法
CN105471823B (zh) * 2014-09-03 2018-10-26 阿里巴巴集团控股有限公司 一种敏感信息处理方法、装置、服务器及安全判定系统
WO2016115869A1 (zh) * 2015-01-21 2016-07-28 中国科学院合肥物质科学研究院 Flt3激酶的新型抑制剂及其用途

Also Published As

Publication number Publication date
RU2017128308A (ru) 2019-02-14
JP2021035947A (ja) 2021-03-04
US20180009814A1 (en) 2018-01-11
BR112017015206A2 (pt) 2018-06-19
MX394327B (es) 2025-03-24
HK1246293A1 (zh) 2018-09-07
IL322449A (en) 2025-09-01
IL274716A (en) 2020-07-30
ZA201704338B (en) 2023-10-25
WO2016115356A1 (en) 2016-07-21
SG11201705678YA (en) 2017-08-30
US20220098200A1 (en) 2022-03-31
EP3245208A4 (en) 2018-10-17
MX2019008815A (es) 2019-09-26
CN107108640A (zh) 2017-08-29
MX366827B (es) 2019-07-25
EP3245208A1 (en) 2017-11-22
JP2018502077A (ja) 2018-01-25
CA2971460A1 (en) 2016-07-21
US20200347064A1 (en) 2020-11-05
US20240158400A1 (en) 2024-05-16
MA41350A (fr) 2017-11-21
SG10201906517VA (en) 2019-08-27
CA2971460C (en) 2023-10-10
US20190367518A1 (en) 2019-12-05
KR20170102887A (ko) 2017-09-12
RU2017128308A3 (enExample) 2019-10-24
AU2016206693A1 (en) 2017-07-13
US20250197404A1 (en) 2025-06-19
CN113816962A (zh) 2021-12-21
IL253020A0 (en) 2017-08-31
AU2020230323A1 (en) 2020-10-01
IL308276A (en) 2024-01-01
BR112017015206B1 (pt) 2023-04-11
MX2017009154A (es) 2017-10-12

Similar Documents

Publication Publication Date Title
CA2971460C (en) Synthesis of a bruton's tyrosine kinase inhibitor
TWI658042B (zh) 雜環化合物的合成
CA3075968C (en) Process for the preparation of 7-(4,7-diazaspiro[2,5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one derivatives
AU2015243005A1 (en) Method for producing methyl-{4,6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridino-3-yl]pyrimidino-5-yl}methyl carbamate and its purification for use thereof as pharmaceutical substance
RS58454B1 (sr) Postupak za pripremu jedinjenja diariltiohidantoina
CA2966800A1 (en) Synthesis of copanlisib and its dihydrochloride salt
WO2022204947A1 (zh) 一种连接基药物偶联物的制备方法及其中间体
CN115385926B (zh) 一种连接基药物偶联物的制备方法及其中间体
JP7025411B2 (ja) インドールカルボキサミド化合物の製造方法
CN108699072B (zh) 用于制备7h-吡咯并[2,3-d]嘧啶化合物的方法
HK1212976A1 (zh) 用於制备稠合杂环离子通道调节剂的方法
WO2016071382A1 (en) Synthesis of pi3k inhibitor and salts thereof
EP2057166B1 (en) Process and intermediates for the synthesis of (3-alkyl-5-piperidin-1-yl-3,3a-dihydropyrazolo[1,5-a]pyrimidin-7-yl)-amino derivatives
BR122022026564B1 (pt) Processos para a preparação de 1-((r)-3-(4-amino-3-(4-fenoxifenil)-1hpirazol[3,4-d]pirimidin-1-il)piperidin-1-il)prop-2-en-1-ona (ibrutinibe) e compostos
WO2017130221A1 (en) Improved process for the preparation of idelalisib
CN101627041A (zh) 合成(3-烷基-5-哌啶-1-基-3,3a-二氢-吡唑并[1,5-a]嘧啶-7-基)-氨基衍生物和中间体的方法和中间体
WO2022202814A1 (ja) ピリミジン化合物の製造方法
CN116406365A (zh) 用于制备1-甲基-6-[6-R2-5-甲基-8-(甲基氨基)-4-[(3aS,6aS)-5-甲基-2,3,3a,4,6,6a-六氢吡咯并[2,3-c]吡咯-1-基]-9H-吡啶并[2,3-b]吲哚-3-基]-4-氧代-1,8-萘啶-3-甲酸盐酸盐的方法

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20231128